Skip to main content

Table 3 Locoregional recurrence, distant metastasis, and survival outcomes for patients with limited stage small cell lung cancer (LS-SCLC) treated with chemoradiation, (n = 105)

From: The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer

Outcomes

Rate

Two-year LRRa

38%

Two-year in-field LRR rate

31%

Median time to LRR (months, range)

8.6 (2.5–47.3)

Median time to in-field LRR (months, range)

8.5 (2.5–47.3)

Two-year DMb rate

52%

Median time to DM (months)

8.8 (1.6–74.5)

Two-year any progression rate

62%

Median time to any progression (months, range)

8.4 (1.6–26.2)

Two-year OSc rate

47%

Median survival (months, range)

16.5 (0.6–98.6)

  1. aLRR loco-regional recurrence, bDM distant metastasis, cOS overall survival